AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago [Yahoo! Finance]
AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.